This study assesses cardiovascular injury and cardiac fitness in patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) receiving model based personalized chemoradiation. The goal of this study is to learn more about the risk of developing heart disease as a result of chemoradiation treatment for lung cancer. Researchers also want to learn if the risk can be reduced by using a patient's individual risk profile to guide cancer treatment and help protect the heart.
Patient with histologic diagnosis of non-small cell lung cancer, small cell lung cancer, or limited stage - small cell lung cancer (L-SCLC)
The recommended treatment is thoracic radiation therapy combined with concurrent systemic therapy (chemotherapy and/or immunotherapy) with or without neoadjuvant and/or adjuvant systemic therapy (chemotherapy, immunotherapy, targeted therapy)
>/= 18 years of age
KPS >/= 70
Unable or unwilling to give written informed consent
Previous history of RT to the thorax overlapping with the current treatment field.
Pregnant or breast-feeding
Renal failure necessitating dialysis
M.D. Anderson Cancer Center
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator